Association of Lipid Mediators With Development of Future Incident Inflammatory Arthritis in an Anti-Citrullinated Protein Antibody-Positive Population.


Journal

Arthritis & rheumatology (Hoboken, N.J.)
ISSN: 2326-5205
Titre abrégé: Arthritis Rheumatol
Pays: United States
ID NLM: 101623795

Informations de publication

Date de publication:
06 2021
Historique:
received: 18 05 2020
accepted: 23 12 2020
pubmed: 1 1 2021
medline: 13 8 2021
entrez: 31 12 2020
Statut: ppublish

Résumé

To determine the association of polyunsaturated fatty acid (PUFA)-derived lipid mediators with progression from rheumatoid arthritis (RA)-related autoimmunity to inflammatory arthritis (IA). We conducted a prospective cohort study using data from the Studies of the Etiology of Rheumatoid Arthritis (SERA). SERA enrolled first-degree relatives (FDRs) of individuals with RA (FDR cohort) and individuals who screened positive for RA-related autoantibodies at health fairs (screened cohort). We followed up 133 anti-cyclic citrullinated peptide 3.1 (anti-CCP3.1)-positive participants, 29 of whom developed IA. Lipid mediators selected a priori were quantified from stored plasma samples using liquid chromatography tandem mass spectrometry. We fit multivariable Cox proportional hazards models for each lipid mediator as a time-varying variable. For lipid mediators found to be significantly associated with IA, we then examined interleukin-1β (IL-1β), IL-6, IL-8, and tumor necrosis factor (TNF) as potential statistical mediators. For every 1 natural log pg/ml increase in the circulating plasma levels of proinflammatory 5-HETE, the risk of developing IA increased by 241% (hazard ratio 2.41 [95% confidence interval 1.43-4.07]) after adjusting for age at baseline, cohort (FDR or screened), and shared epitope status. The models examining 15-HETE and 17-HDHA had the same trend but did not reach significance. We did not find evidence that the association between 5-HETE and IA risk was influenced by the proinflammatory cytokines tested. In a prospective cohort of anti-CCP-positive individuals, higher levels of 5-HETE, an important precursor to proinflammatory leukotrienes, is associated with subsequent IA. Our findings highlight the potential significance of these PUFA metabolites in pre-RA populations.

Identifiants

pubmed: 33381911
doi: 10.1002/art.41631
pmc: PMC8169523
mid: NIHMS1657920
doi:

Substances chimiques

Anti-Citrullinated Protein Antibodies 0
CXCL8 protein, human 0
Fatty Acids, Unsaturated 0
Hydroxyeicosatetraenoic Acids 0
IL1B protein, human 0
IL6 protein, human 0
Interleukin-1beta 0
Interleukin-6 0
Interleukin-8 0
TNF protein, human 0
Tumor Necrosis Factor-alpha 0
Docosahexaenoic Acids 25167-62-8
5-hydroxy-6,8,11,14-eicosatetraenoic acid 467RNW8T91
15-hydroxy-5,8,11,13-eicosatetraenoic acid 73945-47-8
17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid 90780-52-2

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

955-962

Subventions

Organisme : NIAMS NIH HHS
ID : K23 AR051461
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI101981
Pays : United States
Organisme : NIAMS NIH HHS
ID : T32 AR007534
Pays : United States
Organisme : NIAMS NIH HHS
ID : R01 AR051394
Pays : United States

Informations de copyright

© 2020, American College of Rheumatology.

Références

Ann Rheum Dis. 2013 Jun;72(6):901-7
pubmed: 22915618
Ann Rheum Dis. 2003 Jun;62(6):501-9
pubmed: 12759283
Arthritis Rheum. 2010 Nov;62(11):3161-72
pubmed: 20597112
JCI Insight. 2016 Apr 21;1(5):e85922
pubmed: 27158677
Ann Rheum Dis. 2018 Jul;77(7):981-987
pubmed: 29436473
Ann Rheum Dis. 2007 Jun;66(6):712-9
pubmed: 16901957
Circ Res. 2020 Jan 3;126(1):75-90
pubmed: 31829100
Curr Top Med Chem. 2011;11(6):629-47
pubmed: 21261595
Ann Rheum Dis. 2008 Jun;67(6):860-6
pubmed: 17644543
Arthritis Rheum. 1998 Oct;41(10):1748-59
pubmed: 9778216
J Immunol. 2016 Sep 15;197(6):2362-8
pubmed: 27534559
Arthritis Rheum. 2010 Feb;62(2):383-91
pubmed: 20112361
Rheumatology (Oxford). 2017 Dec 1;56(12):2229-2236
pubmed: 29029330
Toxicol Sci. 2018 Jun 1;163(2):466-477
pubmed: 29471542
J Rheumatol. 2007 Nov;34(11):2144-53
pubmed: 17918787
Nat Rev Immunol. 2016 Jan;16(1):51-67
pubmed: 26688348
J Thromb Haemost. 2015 Jun;13(6):893-908
pubmed: 25900780
Science. 2010 Jan 29;327(5965):580-3
pubmed: 20110505
Mol Aspects Med. 2017 Dec;58:57-64
pubmed: 28456616
Immunity. 2014 Mar 20;40(3):315-27
pubmed: 24656045
J Clin Invest. 2001 Dec;108(12):1745-7
pubmed: 11748257
Arthritis Res Ther. 2015 Aug 24;17:209
pubmed: 26268317
J Immunol. 2014 Oct 1;193(7):3769-78
pubmed: 25172497
J Chromatogr B Analyt Technol Biomed Life Sci. 2018 Feb 15;1076:35-43
pubmed: 29396366
Curr Rheumatol Rep. 2014 May;16(5):419
pubmed: 24643396
Biochim Biophys Acta. 2012 Nov;1821(11):1415-24
pubmed: 22841830
J Leukoc Biol. 2019 Aug;106(2):241-257
pubmed: 30576001
PLoS One. 2012;7(5):e35296
pubmed: 22662108
Arthritis Rheum. 2009 Dec 15;61(12):1735-42
pubmed: 19950324
Front Immunol. 2019 Sep 27;10:2241
pubmed: 31611873
Arthritis Rheum. 2009 Mar;60(3):641-52
pubmed: 19248103
J Immunol. 2010 Jun 1;184(11):6418-26
pubmed: 20435922
Neuroscience. 2014 Jul 25;273:65-78
pubmed: 24836854
Kidney Int. 1995 May;47(5):1295-302
pubmed: 7543622
Arthritis Rheum. 2008 Jan;58(1):15-25
pubmed: 18163481
Sci Rep. 2019 Aug 19;9(1):12033
pubmed: 31427689
Rheum Dis Clin North Am. 2010 May;36(2):213-41
pubmed: 20510231

Auteurs

Kristen J Polinski (KJ)

Colorado School of Public Health, Aurora.

Elizabeth A Bemis (EA)

Colorado School of Public Health, Aurora.

Fan Yang (F)

Colorado School of Public Health, Aurora.

Tessa Crume (T)

Colorado School of Public Health, Aurora.

M Kristen Demoruelle (MK)

University of Colorado School of Medicine, Aurora.

Marie Feser (M)

University of Colorado School of Medicine, Aurora.

Jennifer Seifert (J)

Colorado School of Public Health, Aurora.

James R O'Dell (JR)

University of Nebraska Medical Center, Omaha.

Ted R Mikuls (TR)

University of Nebraska Medical Center, Omaha.

Michael H Weisman (MH)

Cedars-Sinai Medical Center, Los Angeles, California.

Peter K Gregersen (PK)

Feinstein Institutes for Medical Research, Manhasset, New York.

Richard M Keating (RM)

University of Chicago, Chicago, Illinois.

Jane Buckner (J)

Benaroya Research Institute at Virginia Mason, Seattle, Washington.

Nichole Reisdorph (N)

University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora.

Kevin D Deane (KD)

University of Colorado School of Medicine, Aurora.

Michael Clare-Salzler (M)

University of Florida College of Medicine, Gainesville.

V Michael Holers (VM)

University of Colorado School of Medicine, Aurora.

Jill M Norris (JM)

Colorado School of Public Health, Aurora.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH